{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-036273","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.866931+00:00","generated_at":"2026-06-17T17:04:21.998101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M","bullets":["Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.","Revenue of $44.7M, primarily from AstraZeneca Vaxzevria milestones/royalties, up from $0.3M in 2021.","Cash of $194.4M at Dec 31, 2022, down from $214.1M; operating cash used $14.4M, capital expenditures $5.8M.","R&D expenses of $42.4M (up 108% YoY) driven by VTP-300 HBV, SNAPvax programs, and headcount growth.","Appointed Dr. Nadège Pelletier as CSO in Jan 2023; interim data readouts for VTP-300 and VTP-200 expected in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-036273","json":"https://secwatch.observer/filing/0001104659-23-036273.json","markdown":"https://secwatch.observer/filing/0001104659-23-036273.md","text":"https://secwatch.observer/filing/0001104659-23-036273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/0001104659-23-036273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/tm2310111d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:04:21.998101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"819ad2872cd9fb1135822e2953f6ca24724617d1","claim":"Barinthus Biotherapeutics plc. reported the full year ended December 31, 2022 results: revenue $43.7 million.","evidence_excerpt":"The Company’s share of milestone and royalty payments received by Oxford University Innovation (OUI) from AstraZeneca which were recognized as revenue for the year ended December 31, 2022 amounted to $43.7 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/0001104659-23-036273-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$43.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}